Search the Newsreel

Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary

Vivos Therapeutics, Inc. reported its second-quarter 2026 financial results, showing revenue of $5.15 million, a 35% increase year-over-year. Despite the revenue growth, the company's net loss attributable to stockholders widened to $5.48 million, though diluted loss per share narrowed to $(0.31) due to an …

Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com

This article reports that Vivos Therapeutics Inc filed a Form 8K on August 11. It's a brief financial news item from Investing.com, noting the filing for the company with the stock symbol VVOS.

Vivos Therapeutics Strengthens IP for Sleep Apnea Devices

Vivos Oral Appliance Shows Improvement in Insomnia Severity

A single-site clinical study found that Vivos Therapeutics Inc's Vida oral appliance significantly improved insomnia severity in 100% of its 37 adult participants, reducing Insomnia Severity Index scores by an average of 65%. All patients saw at least one classification level improvement, with many …

Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS)

Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife have jointly disclosed a 9.25% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 1,812,031 shares. This filing, a Schedule 13G, indicates they hold sole voting and dispositive power over these shares, based on …

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

Vivos Therapeutics is expanding its partnership with Greenway Health to implement the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada. This collaboration aims to generate significant annual value through increased patient capacity, improved revenue cycles, and substantial …

Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada

Vivos Therapeutics is expanding its partnership with Greenway Health to deploy the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada (SCN). This initiative is estimated to generate about $9.1 million in annual value for Vivos at SCN, …

Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada

Vivos Therapeutics has partnered with Greenway Health to integrate its AI-powered Novare platform into Vivos' Sleep Centers of Nevada, projecting up to $9.1 million in annual value from increased patient capacity and revenue cycle improvements. This AI implementation is expected to save Vivos $1.8 …

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190), broadening protection for its Vivos CARE oral medical device technology. This continuation patent, along with a previously issued patent, strengthens the intellectual property around their devices, which have received unprecedented FDA clearances …

Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Vivos sleep apnea devices gain broader protection after new patent

Vivos Therapeutics announced that the U.S. Patent and Trademark Office has issued a new patent, No. 12,697,190, which broadens protection for its Vivos CARE oral medical devices for sleep apnea treatment. This new patent is a continuation of a prior patent from 2024, providing …

Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market

Vivos Therapeutics (VVOS) stock surged 36.3% in post-market trading today, reaching $1.54 after closing the regular session down 0.82% at $1.13. This significant jump follows recent positive momentum for the company.

Enterprise value to EBIT forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS

The article discusses the enterprise value to EBIT forward for Vivos Therapeutics, Inc. (NASDAQ:VVOS). It highlights financial data related to the company, indicating the current period value, changes, and percentage changes, provided by FactSet Research Systems Inc. and ICE Data Services.

Vivos Therapeutics Inc (VVOS) Financial Health: Profitability & Balance Sheet Analysis

Vivos Therapeutics Inc (VVOS) currently holds a weak financial score of 5.33, ranking 196 out of 199 in the Healthcare Equipment & Supplies industry, indicating low operating efficiency. Despite its weak financial status, the company reported significant year-over-year growth in its latest quarterly revenue …

Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vivos Therapeutics Inc (VVOS), focusing on its support and resistance levels, key indicators, and moving averages. According to the analysis, VVOS has a current price momentum score of 5.17, trading between a resistance level of $0.51 and …

Vivos Therapeutics Inc (VVOS) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Vivos Therapeutics Inc (VVOS). It provides key financial data for VVOS, including its market cap and recent stock performance. The article details institutional shareholdings and recent changes in those holdings, highlighting specific investors and …

Vivos Therapeutics Inc (VVOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering business segments for FY2025Q3. The company's main revenue streams include sleep testing services, appliance sales to integrated providers, and center revenue, along with smaller contributions from sponsorships, …

VVOS|Vivos Therapeutics Inc|Price:0.390|Chg%:-0.013

This article provides a comprehensive stock analysis of Vivos Therapeutics Inc (VVOS) from TradingKey, highlighting its financial health, growth potential, valuation, and analyst ratings. The company is focused on medical technology for sleep wellness, particularly obstructive sleep apnea. Despite solid past revenue growth, the …

Vivos Therapeutics Inc (VVOS) Cash Flow

This article provides a detailed cash flow statement for Vivos Therapeutics Inc (VVOS), covering quarterly and annual data for various cash flow activities including operating, investing, and financing. It also includes key financial metrics like net income, capital expenditures, and free cash flow, alongside …

Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS

This article provides a detailed revenue breakdown for Vivos Therapeutics Inc (VVOS) as of April 6, covering business segments for FY2025Q3. The company's main revenue streams include sleep testing services, appliance sales to integrated providers, and center revenue, along with smaller contributions from sponsorships, …

Vivos Therapeutics Inc (VVOS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Vivos Therapeutics Inc (VVOS) from TradingKey. It shows that VVOS has not distributed dividends in the past five years but underwent a 25-to-1 merger-related stock split on October 26, 2023. The page also displays …

Vivos Therapeutics Inc (VVOS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Vivos Therapeutics Inc (VVOS), identifying major individual and corporate shareholders, and providing a breakdown of shareholder types. It also presents institutional shareholding data over several quarters, including the number of institutions, shares held, and proportional changes. Additionally, …

Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts

Vivos Therapeutics' (VVOS) fair value estimate has been reduced from US$2.45 to US$2.12 per share, reflecting analyst concerns over balance sheet reinforcement and potential equity dilution. Despite some analysts still seeing value, the updated targets are influenced by the need for significant capital raising …

Investor group takes 19.9% position in Vivos Therapeutics (VVOS)

An investor group, including V-CO Investors LLC and Michael C. Skaff, has reported a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 2,783,102 common shares. This position stems from a $1.6 million subscription by V-Co 4, which included the conversion of a …

Vivos Therapeutics (VVOS) Stock Sees Fair Value Moves Lower As Analysts Reset Growth Assumptions

VVOS Forecast — Price Target — Prediction for 2027

Vivos Therapeutics (VVOS) Slides 6% as Selling Pressure Intensifies Near Key Support - Systematic Flow